Brenan L*, Andreev A*, Cohen O, et al. Phenotypic characterization of a comprehensive set of MAPK1/ERK2 missense mutants. Cell Rep. 2016;17(4):1171-1183. *equal contribution.
Johannessen CM, Boehm JS. Progress towards precision functional genomics. Curr Opin Syst Biol. 2017;2:74-83.
Johannessen CM, Johnson LA, Piccioni F, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013;504(7478):138-142.
Cory Johannessen, Ph.D.
Cory Johannessen is a senior group leader in the Cancer Program of the Broad Institute of MIT and Harvard, where he leads an interdisciplinary, inter-institutional team of scientists focused on solving drug resistance through the discovery of drug combinations. In addition, he leads a research lab aimed at developing new tools and approaches to catalyze the translation of genomic information into cancer therapeutics.
Johannessen joined the Broad Institute in 2008 as a postdoctoral associate with a joint appointment at the Dana-Farber Cancer Institute and Harvard Medical School. In 2014, he moved into the post of research scientist II and became group leader for the Drug Resistance & Combinations Group in 2015. He was named senior group leader in 2016.
During his tenure at the Broad Institute, Johannessen was awarded the Broad Excellence Award for Collaboration as well as the NextGen Award and the William Guy Forbeck Research Foundation Scholar Award. He also served as an instructor at Harvard Medical School from 2011 to 2014. Prior to his graduate studies, he worked as a research technician in the lab of Dr. Leif W. Ellisen at Massachusetts General Hospital Cancer Center in Boston.
Johannessen obtained his Ph.D. in biological and biomedical sciences from Harvard, supervised by Karen M. Cichowski. He also holds an undergraduate degree from Wheaton College, where he worked as an undergraduate research fellow in the lab of Edmund Y. Tong.
Contact Cory Johannessen via email at email@example.com.